Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma

Inclusion Criteria:• Informed consent * Age \> 18 years * Performance status 0-1; expected survival ≥ 3 months * Patient with histologically or cytologically adenocarcinoma developed from cells in the gall bladder, extra- or intrahepatic bile ducts or malignant cells consistent with above mentioned and radiologic findings consistent with cholangiocarcinoma * Liver metastases not suitable for surgery or other local treatment * Extrahepatic disease should be excluded by PET-CT-scan. * Prior treatment with chemotherapy or no progression on first line treatment * Metastases \< 70 % of the liver * neutrophile granulocytes ≥ 1.5 x 109/l og thrombocytes ≥ 100 x 109/l * bilirubin \< 2.0 x UNL (upper normal limit). * creatinine-clearance ≥ 30 ml/min. * INR \< 2. * Intrahepatic treatment can be accomplished * The patients is approved by a multidisciplinary team Exclusion Criteria:• Other current or prior malignant disease except adequately treated and cured carcinoma in situ of the cervix or squamous cell carcinoma of the skin. * Cytotoxic or experimental treatment within a 14 days period before start of trial medication * The patient is not allowed to participate in other clinical trials. * Any clinical symptoms suggesting peripheral neuropathy grade 2 * Other severe medical conditions * Severe cardial disease or AMI \< 1 year * Presence of diseases preventing oral therapy * Patients with uncontrolled infection * Pregnant or lactating women * Women capable of childbearing not using a sufficient method of birth control * Patients not able to understand the treatment or to collaborate * Prior serious or unsuspected reaction after treatment with fluoropyrimidine * Known prior hypersensitivity reactions to the agents * Interstitial pneumonitis or pulmonary fibrosis